Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Oudom Kour"'
Autor:
Matthew Wieduwilt, Jun Yin, Oudom Kour, Rebecca Teske, Wendy Stock, Ken Byrd, Kimberly Doucette, James Mangan, Gregory Masters, Alice Mims, Katarzyna Jamieson, Shira Dinner, Ali Bseiso, Geoffrey Uy, Harry Erba, Mark Litzow, Richard Stone
Publikováno v:
HemaSphere, Vol 7, p e08838b7 (2023)
Externí odkaz:
https://doaj.org/article/bc722a884b7546daaafb895d77286834
Autor:
David Zahrieh, Shauna L. Hillman, Angelina D. Tan, Jennifer L. Frank, Travis Dockter, Bobbi Jo Meyers, Cassie L. Cherevko, Elizabeth S. Peil, Shaylene McCue, Oudom Kour, Heather J. Gunn, Heather B. Neuman, George J. Chang, Electra D. Paskett, Sumithra J. Mandrekar, Amylou C. Dueck
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-13 (2022)
Abstract Introduction Alliance for Clinical Trials in Oncology (Alliance) coordinated trials utilize Medidata Rave® (Rave) as the primary clinical data capture system. A growing number of innovative and complex cancer care delivery research (CCDR) t
Externí odkaz:
https://doaj.org/article/4735ccaab1ad467b99542789d0367e53
Autor:
Harry H, Yoon, Zhaohui, Jin, Oudom, Kour, Lionel Aurelien, Kankeu Fonkoua, Kohei, Shitara, Michael K, Gibson, Larry J, Prokop, Markus, Moehler, Yoon-Koo, Kang, Qian, Shi, Jaffer A, Ajani
Publikováno v:
JAMA Oncology. 8:1456
ImportanceApproval by the US Food and Drug Administration of immune checkpoint inhibition (ICI) for advanced gastroesophageal cancer (aGEC) irrespective of PD-L1 status has generated controversy. Exploratory analyses from individual trials indicate a
Autor:
Harry H. Yoon, Zhaohui Jin, Oudom Kour, Kohei Shitara, Michael K. Gibson, Larry Prokop, Yoon-Koo Kang, Qian Shi, Jaffer A. Ajani
Publikováno v:
Journal of Clinical Oncology. 40:344-344
344 Background: ICI with anti-PD-1 therapy was approved by the US FDA as 1st/2nd-line treatment of advanced GEC regardless of PD-L1 status. It is argued that patients (pts) with PD-L1-low GEC do not benefit from ICI. To avoid spurious exclusion of pt